National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meeting, 41914 [E9-19889]
Download as PDF
<![CDATA[
41914
Federal Register / Vol. 74, No. 159 / Wednesday, August 19, 2009 / Notices
beginning in the fall, 2009, with funding
to commence in spring, 2010. Interested
parties may sign up to receive updates
about AHRQ’s Effective Health Care
Program at https://
effectivehealthcare.ahrq.gov/.
ADDRESSES: The future CER solicitations
will be published in the NIH Guide:
https://grants.nih.gov/grants/guide/
index.html.
FOR FURTHER INFORMATION CONTACT:
Until the solicitations are published,
AHRQ cannot provide information on
their contents.
Direct any general comments
regarding the Effective Health Care
program to: Lia Hotchkiss, MPH, PMP,
Center for Outcomes and Evidence,
Agency for Healthcare Research and
Quality, 540 Gaither Road, Rockville,
MD 20850, Telephone: 301–427–1502,
E-mail address:
Effectivehealthcare@ahrq.hhs.gov.
SUPPLEMENTARY INFORMATION:
jlentini on DSKJ8SOYB1PROD with NOTICES
Background
The Agency for Healthcare Research
and Quality (AHRQ) has been
supporting comparative effectiveness
research for many years and since 2005
through AHRQ’s Effective Health Care
Program, which was authorized under
Section 1013 of the Medicare
Prescription Drug, Improvement, and
Modernization Act of 2003. The
Effective Health Care program provides
systematic reviews and develops other
translational information and tools
designed to inform health care decision
making. The Effective Health Care
Program advances the methodology of
comparative effectiveness research
(CER) and provides training grants to
enhance the pool of researchers who can
perform CER.
Comparative Effectiveness Research
Initiative Description
Funding Opportunity
Announcements soliciting research
grant applications for CER will provide
$148 million for evidence generation.
This includes $100 million for the
Clinical and Health Outcomes Initiative
in Comparative Effectiveness (CHOICE),
a new, coordinated, national effort to
establish a series of prospective
pragmatic clinical comparative
effectiveness studies that measure the
benefits treatments produce in routine
clinical practice and will include novel
study designs focusing on real-world
and under-represented populations
(children, elderly, racial and ethnic
minorities, and other understudied
populations), and $48 million for the
establishment or enhancement of
national patient registries that can be
VerDate Nov<24>2008
16:53 Aug 18, 2009
Jkt 217001
used for researching the longitudinal
effects of different interventions and
collecting data on under-represented
populations. Additional grant funding is
expected to include $29.5 million to
support innovative translation and
dissemination grants related to CER, as
well as $20 million to support training
and career development in CER.
Requests for Contracts for CER will
provide $9.5 million to establish an
infrastructure to identify new and/or
emerging issues for comparative
effectiveness review investments. Also,
$10 million will establish a Citizen’s
Forum to formally engage all
stakeholders, and to expand and
standardize public involvement in the
entire Effective Health Care enterprise.
Additionally, AHRQ anticipates
supporting other grants ($1 million) and
enhancing existing contracts for
evidence synthesis ($50 million),
evidence generation ($24 million),
translation and dissemination ($5
million), and salary and benefits for
ARRA-related full-time equivalent
positions ($3 million).
Place: Bethesda Marriott Suites, 6711
Democracy Boulevard, Bethesda, MD 20817.
Contact Person: D. G. Patel, PhD, Scientific
Review Officer, Review Branch, DEA,
NIDDK, National Institutes of Health, Room
756, 6707 Democracy Boulevard, Bethesda,
MD 20892–5452, (301) 594–7682,
pateldg@niddk.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Endocrinology and Metabolic Research;
93.848, Digestive Diseases and Nutrition
Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes
of Health, HHS)
Dated: August 11, 2009.
Carolyn M. Clancy,
AHRQ, Director.
[FR Doc. E9–19758 Filed 8–18–09; 8:45 am]
Pursuant to section 10(a) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of a meeting of the
Recombinant DNA Advisory Committee.
The meeting will be open to the
public, with attendance limited to space
available. Individuals who plan to
attend and need special assistance, such
as sign language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
BILLING CODE 4160–90–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; P01 Application.
Date: October 28, 2009.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
PO 00000
Frm 00054
Fmt 4703
Sfmt 4703
Dated: August 11, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E9–19889 Filed 8–18–09; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Office of the Director, National
Institutes of Health; Notice of Meeting
Name of Committee: Recombinant DNA
Advisory Committee.
Date: September 9–10, 2009.
Time: September 9, 2009, 1:15 p.m. to 5:45
p.m.
Agenda: The Recombinant DNA Advisory
Committee will review and discuss selected
human gene transfer protocols as well as
related data management activities. Please
check the meeting agenda at https://
oba.od.nih.gov/rdna/rdna.html for more
information.
Place: Hilton Washington/Rockville, 1750
Rockville Pike, Rockville, MD 20852.
Time: September 10, 2009, 8:30 a.m. to 11
a.m.
Agenda: The Recombinant DNA Advisory
Committee will review and discuss selected
human gene transfer protocols as well as
related data management activities. Please
check the meeting agenda at https://
oba.od.nih.gov/rdna/rdna.html for more
information.
Place: Hilton Washington/Rockville, 1750
Rockville Pike, Rockville, MD 20852.
Contact Person: Laurie Lewallen, Advisory
Committee Coordinator, Office of
Biotechnology Activities, National Institutes
of Health, 6705 Rockledge Drive, Room 750,
E:\FR\FM\19AUN1.SGM
19AUN1
]]>Agencies
[Federal Register Volume 74, Number 159 (Wednesday, August 19, 2009)]
[Notices]
[Page 41914]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-19889]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and Digestive and Kidney Diseases;
Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Diabetes and Digestive
and Kidney Diseases Special Emphasis Panel; P01 Application.
Date: October 28, 2009.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant applications.
Place: Bethesda Marriott Suites, 6711 Democracy Boulevard,
Bethesda, MD 20817.
Contact Person: D. G. Patel, PhD, Scientific Review Officer,
Review Branch, DEA, NIDDK, National Institutes of Health, Room 756,
6707 Democracy Boulevard, Bethesda, MD 20892-5452, (301) 594-7682,
pateldg@niddk.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.847,
Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive
Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes of Health, HHS)
Dated: August 11, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. E9-19889 Filed 8-18-09; 8:45 am]
BILLING CODE 4140-01-P
